Cargando…

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'

Detalles Bibliográficos
Autores principales:	Klok, Frederikus A., Versteeg, Henri H., Verschoor, Arie J., Huisman, Menno V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461990/ https://www.ncbi.nlm.nih.gov/pubmed/30696981 http://dx.doi.org/10.1038/s41416-018-0361-x

Ejemplares similares

Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Jara-Palomares, Luis, et al.
Publicado: (2019)

D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
por: Jara-Palomares, Luis, et al.
Publicado: (2018)

The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis
por: Tamizifar, Babak, et al.
Publicado: (2014)

The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis
por: van Hylckama Vlieg, Marte A.M., et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Comment from Huisman et al.
por: Huisman, Menno V., et al.
Publicado: (2022)

Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark
por: Klok, Frederikus A., et al.
Publicado: (2020)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer
por: Anijs, Rayna J. S., et al.
Publicado: (2022)

Response: Comment on “Significant decrease in plasma D‐dimer levels and mean platelet volume after a 3‐month treatment with rosuvastatin in patients with venous thromboembolism”
por: Alirezaei, Toktam, et al.
Publicado: (2022)

Author response to: Comment on: Timing of symptomatic venous thromboembolism after surgery: meta-analysis
por: Singh, Tino, et al.
Publicado: (2023)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

First do no harm
por: Huisman, Menno V., et al.
Publicado: (2022)

Reply to the authors of “Age-adjusted D-dimer cut-off levels to exclude venous thromboembolism in COVID-19 patients”()
por: Godon, Alexandre, et al.
Publicado: (2021)

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study
por: Mahé, Isabelle, et al.
Publicado: (2021)

D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants
por: Legnani, Cristina, et al.
Publicado: (2019)

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2019)

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
por: Kooiman, Judith, et al.
Publicado: (2015)

Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations
por: Nab, Linda, et al.
Publicado: (2022)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study
por: Harel, Ziv, et al.
Publicado: (2022)

Prophylaxis and treatment of COVID-19 related venous thromboembolism
por: Kaptein, F.H.J., et al.
Publicado: (2021)

Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19
por: Zuin, Marco, et al.
Publicado: (2021)

Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations
por: Martens, Emily S. L., et al.
Publicado: (2022)

Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism
por: Ende-Verhaar, Yvonne M., et al.
Publicado: (2018)

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Blanco-Molina, Angeles, et al.
Publicado: (2014)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism　― Insights From the J’xactly Study ―
por: Yamashita, Takeshi, et al.
Publicado: (2022)

Effect of Discontinuation of Anticoagulation in Patients with Intracranial Hemorrhage at High Thromboembolic Risk
por: Jung, Hwan-Su, et al.
Publicado: (2014)

Health-related quality of life after first venous thromboembolism in individuals aged 70 years and older
por: Wang, Huijie, et al.
Publicado: (2023)

Vaccine-induced immune thrombotic thrombocytopenia
por: Klok, Frederikus A, et al.
Publicado: (2022)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Acute on Chronic Venous Thromboembolism on Therapeutic Anticoagulation
por: Bassi, Byron, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h8k5p4t1nnp8061tiap3s2j6u4